Physician
Interventional Pain Consultants
Interventional Pain Consultants was paid $586K by Medicaid between Dec 2022 and Dec 2024, across 45 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 58% of everything it billed.
33Billing provider infoINTERVENTIONAL PAIN CONSULTANTS
CLEVELAND, TN 37311
CLEVELAND, TN 37311
33aNPI1174241145assigned 08/16/2022
33bProvider typePain Medicine Physician
28Total paid$586K
24GClaims42,782
24DCodes billed45
24AFirst – last monthDec 2022 – Dec 2024
Compared with peers
Next to other Pain Medicine Physician providers in Tennessee
Rank by total paid#3 of 13
Median peer was paid$31K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 170 | $512.04 | |
| 2023 | 24,896 | $301K | |
| 2024incomplete | 17,716 | $284K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 58% | 17,369 | 14,466 | $337K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 7,994 | 5,908 | $113K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 5.4% | 1,395 | 932 | $31K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.5% | 1,721 | 1,081 | $21K |
| G3002 | Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) | 2.0% | 1,575 | 1,337 | $12K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.0% | 176 | 166 | $6K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 111 | 102 | $5K |
| 83970 | <1% | 384 | 255 | $5K | |
| 80305 | <1% | 373 | 357 | $4K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 391 | 359 | $4K |
| 82670 | <1% | 384 | 255 | $4K | |
| 84403 | <1% | 385 | 255 | $3K |
33 more codes
| 64635 | <1% | 31 | $3K | |
| 81025 | <1% | 781 | $3K | |
| 84146 | <1% | 386 | $2K | |
| 82627 | <1% | 385 | $2K | |
| 84144 | <1% | 384 | $2K | |
| 83001 | <1% | 385 | $2K | |
| 83002 | <1% | 385 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 275 | $2K |
| 84481 | <1% | 385 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 385 | $2K |
| 82533 | <1% | 385 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 189 | $2K |
| 82746 | <1% | 385 | $2K | |
| 82607 | <1% | 385 | $2K | |
| 82728 | <1% | 376 | $1K | |
| 64636 | <1% | 35 | $1K | |
| 84439 | <1% | 385 | $922.85 | |
| 82977 | <1% | 385 | $900.70 | |
| 83735 | <1% | 385 | $870.01 | |
| 83550 | <1% | 245 | $822.08 | |
| 83615 | <1% | 385 | $759.78 | |
| 83540 | <1% | 376 | $719.84 | |
| 86431 | <1% | 385 | $645.49 | |
| 86140 | <1% | 386 | $599.61 | |
| 84550 | <1% | 384 | $576.87 | |
| 80053 | Comprehensive metabolic panel | <1% | 239 | $422.18 |
| 80069 | <1% | 234 | $354.16 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 388 | $338.15 |
| 82962 | <1% | 296 | $297.72 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 82 | $18.13 |
| 84100 | <1% | 144 | $13.34 | |
| 80076 | <1% | 144 | $3.11 | |
| 84436 | <1% | 144 | $3.09 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWIDDIFIELD, KARI (PRACTICE ADMINISTRATOR)